SOURCE: StockCall


June 30, 2011 08:34 ET

Research on Alkermes Inc. and Hospira Inc. - Drug Delivery Companies Looking for New Revenues

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Jun 30, 2011) - offers investors comprehensive research on the Drug Delivery industry and has completed analytical research on Alkermes Inc. (NASDAQ: ALKS) and Hospira Inc. (NYSE: HSP). Register with us today at to have free access to these researches.

Looming patent cliffs are making companies in the Drug Delivery sector work to develop new drugs in fear of revenues lost to generic competition. Alkermes Inc. is helping two other companies to develop a longer lasting version of the diabetes drug Byetta called Bydureon that will hopefully allow it to grow its revenues. The companies' drug recently received approval from European regulators to market the drug, but the FDA is proving more difficult. Investors can register for free to access the research reports on Alkermes Inc. at is an online platform where investors doing their due-diligence on the Drug Delivery industry can have easy and free access to our analyst research and opinions on Alkermes Inc. and Hospira Inc.; investors and shareholders of these companies can simply register for a complimentary membership at

While large cap generic drug makers will likely see growth in the U.S., the sector is also gaining traction in emerging markets where expanding health care systems offer clear opportunities. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

The drug delivery supply chain has taken some heat lately as a shortage of a chemotherapy treatment put many cancer patients at risk. With many calling the current system unreliable, Hospira Inc. is one company that may benefit from the stronger demand created by the shortages. Investors can register for free to access the research reports on Hospira Inc. at

Another huge piece of news for the sector is the approval of generic forms of biologic treatments. The FDA is still figuring out an approval process, but when several biologic drugs lose their patents in the next few years a huge market for bio-similar will open itself up to the sector. Register now at to have free access to our reports on the Drug Delivery industry.

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information